Alexandra Drakaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Drakaki has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Marten Anne Hoeksema
Department of Medical Biochemistry, University of Amsterdam, Amsterdam UMC, Location AMC, Meibergdreef 9, Amsterdam, The Netherlands
3 shared publications Bin Hu
Massey Cancer Center, Virginia Commonwealth University, Richmond, USA
2 shared publicationsEmily Spector
Complex Carbohydrate Research Center, University of Georgia, Athens, USA
2 shared publicationsFarhan Valummel
Department of Biochemistry and Molecular Biology, University of Georgia, Athens, USA
2 shared publications- Jennifer E. Koblinski
Massey Cancer Center, Virginia Commonwealth University, Richmond, USA
2 shared publications - Lance Wells
Complex Carbohydrate Research Center, University of Georgia, Athens, USA
2 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Springer Nature in Communications Biology
A non-canonical EZH2/TRIM28 epigenetic axis drives heparan sulfate remodeling and melanoma metastasis
Melanoma progression is driven not only by oncogenic alterations but also by epigenetic programs that remodel the tumor microenvironment. Heparan sulfate (HS) proteoglycans are extracellular matrix components that control growth factor signaling and cell-matrix interactions, yet how chromatin-associated factors regulate HS remodeling in cancer remains ill-defined. Here, we identify the histone methyltransferase EZH2 as a regulator of HS biosynthesis in melanoma. Bioinformatic and genomic analyses reveal enrichment of EZH2 and additional Polycomb Repressive Complex (PRC) factors at regulatory regions of HS biosynthetic genes. CRISPR-mediated loss of EZH2 modulates expression of multiple HS-modifying enzymes, notably the secreted endosulfatases SULF1 and SULF2, enhancing HS 6- O sulfation and altering ligand binding at the cell surface. Unexpectedly, EZH2 promotes SULF1 through a methyltransferase-independent, non-canonical interaction with TRIM28, whereas SULF2 is repressed through canonical PRC2 activity. Functionally, SULF1 depletion impairs melanoma cell migration and invasion and reduces spontaneous metastasis in vivo. These findings define an epigenetic axis linking chromatin regulation to glycan remodeling and identify HS-modifying enzymes as candidate targets to limit melanoma metastasis.
- 19 September 2026
- Published by Springer Nature in Communications Biology
Open AccessA non-canonical EZH2/TRIM28 epigenetic axis drives heparan sulfate remodeling and melanoma metastasis
Melanoma progression is driven not only by oncogenic alterations but also by epigenetic programs that remodel the tumor microenvironment. Heparan sulfate (HS) proteoglycans are extracellular matrix components that control growth factor signaling and cell-matrix interactions, yet how chromatin-associated factors regulate HS remodeling in cancer remains ill-defined. Here, we identify the histone methyltransferase EZH2 as a regulator of HS biosynthesis in melanoma. Bioinformatic and genomic analyses reveal enrichment of EZH2 and additional Polycomb Repressive Complex (PRC) factors at regulatory regions of HS biosynthetic genes. CRISPR-mediated loss of EZH2 modulates expression of multiple HS-modifying enzymes, notably the secreted endosulfatases SULF1 and SULF2, enhancing HS 6- O sulfation and altering ligand binding at the cell surface. Unexpectedly, EZH2 promotes SULF1 through a methyltransferase-independent, non-canonical interaction with TRIM28, whereas SULF2 is repressed through canonical PRC2 activity. Functionally, SULF1 depletion impairs melanoma cell migration and invasion and reduces spontaneous metastasis in vivo. These findings define an epigenetic axis linking chromatin regulation to glycan remodeling and identify HS-modifying enzymes as candidate targets to limit melanoma metastasis.
- Open Access
- 13 August 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (20) , 7021-7040
Multi-level transcriptional control of specific macrophage responses
Macrophages can adopt diverse functional states in response to environmental cues, a process that is fundamentally controlled at the level of transcriptional regulation. In this review, we outline a hierarchical framework of transcription factor activity that underpins macrophage identity and activation. Firstly, lineage-determining transcription factors establish the cell-type-specific chromatin landscape during development. Upon tissue seeding, local signals shape the activity of additional transcription factors that refine enhancer landscapes and drive tissue-specific macrophage phenotypes. Macrophages further adopt their functional states when exposed to potential threats to tissue homeostasis, such as bacterial ligands or inflammatory cytokines. In response, signal-dependent transcription factors are activated and initiate signal-appropriate transcriptional programs. The specificity and durability of these responses are determined by secondary transcription factors that modulate the magnitude, timing, and maintenance of stimulus-induced transcriptional programs. Collectively, macrophage responses emerge from the activity of interconnected layers of cell-type-, tissue-, and signal-dependent transcription factors, forming complex regulatory networks that inflict stimulus-specific outcomes. Dysregulation of these networks can transcriptionally rewire macrophages toward disease-associated states. Delineating transcriptional regulators that distinguish signal responses may enable more targeted disease interventions.
- 13 August 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (20) , 7021-7040
Open AccessMulti-level transcriptional control of specific macrophage responses
Macrophages can adopt diverse functional states in response to environmental cues, a process that is fundamentally controlled at the level of transcriptional regulation. In this review, we outline a hierarchical framework of transcription factor activity that underpins macrophage identity and activation. Firstly, lineage-determining transcription factors establish the cell-type-specific chromatin landscape during development. Upon tissue seeding, local signals shape the activity of additional transcription factors that refine enhancer landscapes and drive tissue-specific macrophage phenotypes. Macrophages further adopt their functional states when exposed to potential threats to tissue homeostasis, such as bacterial ligands or inflammatory cytokines. In response, signal-dependent transcription factors are activated and initiate signal-appropriate transcriptional programs. The specificity and durability of these responses are determined by secondary transcription factors that modulate the magnitude, timing, and maintenance of stimulus-induced transcriptional programs. Collectively, macrophage responses emerge from the activity of interconnected layers of cell-type-, tissue-, and signal-dependent transcription factors, forming complex regulatory networks that inflict stimulus-specific outcomes. Dysregulation of these networks can transcriptionally rewire macrophages toward disease-associated states. Delineating transcriptional regulators that distinguish signal responses may enable more targeted disease interventions.
- Open Access
A non-canonical EZH2/TRIM28 epigenetic axis drives heparan sulfate remodeling and melanoma metastasis
Melanoma progression and metastasis are driven not only by oncogenic alterations but also by epigenetic programs that dynamically remodel the tumor microenvironment. Heparan sulfate (HS) proteoglycans are key extracellular matrix components that integrate growth factor signaling, cell-matrix interactions, and migratory behavior by controlling ligand availability and receptor engagement, yet how chromatin-associated factors regulate HS remodeling in cancer remains poorly defined. Here, we identify the histone methyltransferase EZH2 as a key regulator of HS biosynthesis in melanoma. Integrated bioinformatic and genomic analyses revealed enrichment of EZH2 and additional Polycomb Repressive Complex (PRC) factors at regulatory regions of HS biosynthetic genes. CRISPR-mediated loss of EZH2 altered expression of multiple HS-modifying enzymes, most notably the secreted endosulfatases SULF1 and SULF2, resulting in enhanced HS 6- O sulfation and altered ligand binding at the cell surface. Unexpectedly, EZH2 promoted SULF1 expression through a methyltransferase-independent mechanism via a non-canonical interaction with TRIM28, whereas SULF2 was regulated through canonical PRC2-mediated repression. Functionally, SULF1 depletion impaired melanoma cell migration and invasion in vitro and reduced spontaneous metastasis in an orthotopic xenograft model. Together, these findings define an epigenetic axis linking chromatin regulation to extracellular glycan remodeling and identify HS-modifying enzymes as candidate targets to limit melanoma metastasis.
Open AccessA non-canonical EZH2/TRIM28 epigenetic axis drives heparan sulfate remodeling and melanoma metastasis
Melanoma progression and metastasis are driven not only by oncogenic alterations but also by epigenetic programs that dynamically remodel the tumor microenvironment. Heparan sulfate (HS) proteoglycans are key extracellular matrix components that integrate growth factor signaling, cell-matrix interactions, and migratory behavior by controlling ligand availability and receptor engagement, yet how chromatin-associated factors regulate HS remodeling in cancer remains poorly defined. Here, we identify the histone methyltransferase EZH2 as a key regulator of HS biosynthesis in melanoma. Integrated bioinformatic and genomic analyses revealed enrichment of EZH2 and additional Polycomb Repressive Complex (PRC) factors at regulatory regions of HS biosynthetic genes. CRISPR-mediated loss of EZH2 altered expression of multiple HS-modifying enzymes, most notably the secreted endosulfatases SULF1 and SULF2, resulting in enhanced HS 6- O sulfation and altered ligand binding at the cell surface. Unexpectedly, EZH2 promoted SULF1 expression through a methyltransferase-independent mechanism via a non-canonical interaction with TRIM28, whereas SULF2 was regulated through canonical PRC2-mediated repression. Functionally, SULF1 depletion impaired melanoma cell migration and invasion in vitro and reduced spontaneous metastasis in an orthotopic xenograft model. Together, these findings define an epigenetic axis linking chromatin regulation to extracellular glycan remodeling and identify HS-modifying enzymes as candidate targets to limit melanoma metastasis.